When Mylan ( $MYL ) quickly settled its Medicaid allegations a week ago with a $465 million payment, analysts and politicians predicted the company’s EpiPen trouble would be far from over. Now, that’s ringing true as the pharma faces a shareholder lawsuit pressing for damages from related share price drops. Bernstein Liebhard announced a class action suit claiming securities violations at Mylan …